Spectral AI, Inc. , a medical diagnostics company leveraging artificial intelligence (AI) to enable faster and more accurate treatment decisions in wound care, has announced the pricing of a $7.6 million offering. The funding will support the company’s ongoing expansion and the further development of its DeepView® System, a proprietary AI-driven imaging platform designed to enhance clinical decision-making.
The transaction involves the issuance of 4,000,000 shares of common stock and pre-funded warrants at a price of $1.90 per share, along with corresponding warrants carrying an exercise price of $2.51 per share of common stock.
J. Michael DiMaio, MD, Chairman of the Board of Spectral AI, stated, “I am pleased that we were able to secure institutional funding for Spectral AI. This financing ensures that we can continue to develop and expand the DeepView System’s clinical indications and prepare for commercial readiness in 2026. We remain fully committed to supporting our current BARDA Project BioShield (PBS) contract, while also advancing our AI-powered technology to broaden our product offerings and deliver innovative solutions to the global medical community.”
Northland Capital Markets served as the exclusive placement agent for the transaction.
Also Read